Trial Profile

ResQ201A: Randomized, Open-Label, Phase 3 Clinical Trial of N-803 Plus Tislelizumab and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 18 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Docetaxel (Primary) ; Nogapendekin alfa inbakicept (Primary) ; Tislelizumab (Primary)
Indications Non-small cell lung cancer; Squamous cell cancer
Focus Registrational; Therapeutic Use
Acronyms ResQ201A
Sponsors ImmunityBio

25 Jul 2025 According to an ImmunityBio media release, US sites in this trial have been initiated and CTA has been submitted for EU and UK. The filings for Canada and Asia are planned. Canada submission is expected in early Q3 2025.
06 May 2025 Planned initiation date changed from 1 Mar 2025 to 1 May 2025.
06 May 2025 Status changed from not yet recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com